Insider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) Director Buys 6,266 Shares of Stock

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III bought 6,266 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was purchased at an average cost of $3.64 per share, with a total value of $22,808.24. Following the completion of the purchase, the director now directly owns 430,058 shares of the company’s stock, valued at $1,565,411.12. This represents a 1.48 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Perspective Therapeutics Stock Down 3.4 %

CATX stock traded down $0.15 during midday trading on Wednesday, reaching $4.25. The company had a trading volume of 649,499 shares, compared to its average volume of 830,402. The company’s 50 day simple moving average is $11.15. Perspective Therapeutics, Inc. has a 1-year low of $2.28 and a 1-year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21). The business had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. On average, analysts anticipate that Perspective Therapeutics, Inc. will post -0.87 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on CATX shares. Wedbush reissued an “outperform” rating and issued a $11.00 target price (down from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $24.00 to $5.00 in a report on Monday. Oppenheimer cut their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Truist Financial started coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price for the company. Finally, Royal Bank of Canada dropped their target price on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a report on Monday. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Perspective Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $15.14.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CATX. nVerses Capital LLC bought a new position in Perspective Therapeutics in the third quarter valued at about $57,000. US Bancorp DE increased its position in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares during the period. Victory Capital Management Inc. acquired a new stake in Perspective Therapeutics during the 2nd quarter valued at approximately $117,000. Point72 DIFC Ltd acquired a new stake in Perspective Therapeutics during the 2nd quarter valued at approximately $118,000. Finally, Intech Investment Management LLC acquired a new stake in Perspective Therapeutics during the 3rd quarter valued at approximately $137,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.